Press release
EP0042 receives Orphan Drug Designation from the US Food and Drug Administration
March 14, 2023Business Services
Ellipses Pharma (“Ellipses”), a global drug development company focused on accelerating the development of cancer medicines and treatments through an …
Teitur Trophics Raises EUR 28M in Series A Financing to Advance the Development and Treatment for Neurodegenerative Diseases
March 14, 2023Business Services
Aarhus, Denmark March 14th, 2023: Teitur Trophics (“Teitur”), a biotech company dedicated to developing new treatments for patients suffering from …
Newron announces 2022 financial results and provides outlook for 2023
March 14, 2023Business Services
Milan, Italy, March 14, 2023, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company …
Cell and Gene Therapy Catapult opens new Process Analytical Technologies laboratory
March 14, 2023Business Services
London, 14 March 2023: The Cell and Gene Therapy Catapult (CGT Catapult) today announces the opening of a new laboratory …
Scottish patients with the most aggressive form of viral hepatitis become first in UK to be offered routine NHS access to Hepcludex® (bulevirtide)
March 14, 2023Business Services
Monday 13 March 2023, London, UK – Gilead Sciences Ltd today announced that the Scottish Medicines Consortium (SMC) has become …
Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301
March 13, 2023Business Services
KANSAS CITY, KANSAS and PRINCETON, NEW JERSEY – March 13, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing …
BRITISH LAND AND AUSTRALIANSUPER ANNOUNCE LIFE SCIENCES AMBITION AT CANADA WATER
March 13, 2023Business Services
13 March 2023
Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy
March 13, 2023Business Services
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled …
FlyPharma Europe, Vienna: 2023 conference officially launched
March 9, 2023Business Services
FlyPharma Europe, Vienna: 2023 conference officially launched FlyPharma Conferences is pleased to announce its seventh event in Europe, which …
MSD presents Phase 3 data for its Investigational Activin Signaling Inhibitor, in Adults with Pulmonary Arterial Hypertension on Background Therapy
March 9, 2023Business Services
LONDON, UK, March 6, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) today announced …
Redx Announces RXC004 Topline Data From a Phase 2 Monotherapy Module
March 8, 2023Business Services
Alderley Park, UK, 8 March 2023 Redx (AIM:REDX), the clinical-stage biotechnology company focused on discovering and developing novel, small molecule, …
POLB 001 patent portfolio strengthened through granting of US patent
March 8, 2023Business Services
8 March 2023 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a leading infectious disease focused biopharmaceutical …
Chiesi Group and Affibody collaborate to develop and commercialize innovative treatments for respiratory diseases
March 7, 2023Business Services
Parma, Italy and Solna, Sweden, March 7th, 2023 – Chiesi Farmaceutici S.p.A (“Chiesi Group”) and Affibody AB (“Affibody”) today announced …
Late-Breaking Phase 3 A DUE Data Show Investigational Single-Tablet Combination Therapy of Macitentan and Tadalafil Significantly Improves Pulmonary Haemodynamics versus Monotherapy in Patients with Pulmonary Arterial Hypertension (PAH)
March 6, 2023Business Services
BEERSE, Belgium, 6 March, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced results from the Phase …
86% of pharma and biotech companies plan to invest in ‘digitally agile’ supply chains in the next 12 months
March 6, 2023Business Services
LONDON 6th March 2023 86% of pharma and biotech companies say they plan to become more digitally agile, according to …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
